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Background Artemisinin combination therapy (ACT) has been the first-line treatment for
uncomplicated malaria in Cameroon since 2004 and Nigeria since 2005, though
many febrile patients receive less effective antimalarials. Patients often rely on
providers to select treatment, and interventions are needed to improve providers’
practice and encourage them to adhere to clinical guidelines.
Methods Providers’ adherence to malaria treatment guidelines was examined using data
collected in Cameroon and Nigeria at public and mission facilities, pharmacies and
drug stores. Providers’ choice of antimalarial was investigated separately for each
country. Multilevel logistic regression was used to determine whether providers
were more likely to choose ACT if they knew it was the first-line antimalarial.
Multiple imputation was used to impute missing data that arose when linking exit
survey responses to details of the provider responsible for selecting treatment.
Results There was a gap between providers’ knowledge and their practice in both
countries, as providers’ decision to supply ACT was not significantly associated
with knowledge of the first-line antimalarial. Providers were, however, more
likely to supply ACT if it was the type of antimalarial they prefer. Other factors
were country-specific, and indicated providers can be influenced by what they
perceived their patients prefer or could afford, as well as information about their
symptoms, previous treatment, the type of outlet and availability of ACT.
Conclusions Public health interventions to improve the treatment of uncomplicated malaria
should strive to change what providers prefer, rather than focus on what they
know. Interventions to improve adherence to malaria treatment guidelines
should emphasize that ACT is the recommended antimalarial, and it should be
used for all patients with uncomplicated malaria. Interventions should also be
tailored to the local setting, as there were differences between the two countries
in providers’ choice of antimalarial, and who or what influenced their practice.
Keywords Cameroon, malaria, multilevel analysis, multiple imputation, Nigeria, provider
practice
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KEY MESSAGES
 Providers’ choice of antimalarial was not determined by their knowledge of the malaria treatment guidelines.
 Providers make treatment decisions based on their preference, attributes of the patient and resources available.
 Strategies to disseminate clinical guidelines need to identify mechanisms that change preference and practice in the local
setting.
Introduction
Clinical guidelines are systematically developed statements to
assist providers’ decision making on the appropriate care for
specific clinical conditions (Field et al. 1992). By establishing
common standards for diagnosis and treatment, they are
central to efforts to improve the quality of health care and
can expedite the introduction of new health technologies
(Cabana et al. 1999; Woolf et al. 2012). Each year governments
invest considerable resources in the development and distribu-
tion of clinical guidelines to ensure providers have access to the
latest scientific evidence. Despite these efforts, there are
challenges translating evidence into practice and patients
often receive substandard care (Grol and Grimshaw 2003).
Moreover, several studies on the performance of health care
providers have identified a knowledge–practice gap, which
suggests that public health interventions to disseminate clinical
guidelines may not be sufficient to change providers’ practice
(Das et al. 2008; Leonard and Masatu 2010).
Over the past decade, national malaria treatment policies
have been revised in all African countries to establish artemi-
sinin combination therapy (ACT) as the first-line treatment for
uncomplicated malaria. However, uptake of ACT has been slow
in some countries and studies undertaken in Cameroon and
Nigeria in 2009, 4 years after ACT became the recommended
first-line treatment, showed that many patients treated for
malaria did not receive an ACT (Mangham et al. 2011; 2012).
The situation in southeast Nigeria was of particular concern as
only 22% of febrile patients seeking treatment at primary health
centres, pharmacies and drugs stores received an ACT
(Mangham et al. 2011). These studies also showed that
providers were routinely responsible for the choice of treatment
at the public and mission facilities and advised on treatment in
more than one-third of cases at pharmacies and drug stores
(Mangham et al. 2011; 2012).
Interventions to improve malaria diagnosis and treatment
have traditionally focused on ensuring providers are informed
about policy changes and have used training and job aids to
improve their knowledge of the clinical guidelines (Smith et al.
2009). However, evidence from intervention and cross-sectional
studies show access to in-service training, guidelines and job
aids often have a limited effect in changing providers’ practice
(Rowe et al. 2000, 2003; Zurovac et al. 2004, 2005; Osterholt
et al. 2006; Zurovac et al. 2008a,b; Smith et al. 2009).
It is timely to explore the relationship between providers’
practice in treating uncomplicated malaria and their knowledge
of the clinical guidelines, as malaria treatment guidelines
undergo further revision to advise on the use of malaria rapid
diagnostic tests (RDTs) and dissemination strategies are being
developed. Moreover, early evidence suggests that malaria RDTs
will only be cost-effective if providers adhere to the malaria
treatment guidelines: testing before treatment should reduce
the number of febrile patients consuming antimalarials that
they do not need, but this requires providers to adhere to the
test results when making treatment decisions (Lubell et al.
2008).
In this article, we examine providers’ adherence to malaria
treatment guidelines at public and mission facilities, pharma-
cies and drug stores in urban and rural areas of Cameroon and
Nigeria prior to the introduction of malaria RDTs. We investi-
gate what influences providers’ choice of antimalarial, and
assess whether providers were more likely to select an ACT if
they knew it was the first-line treatment for uncomplicated
malaria. This exploratory analysis was undertaken to generate
hypotheses and guide the design of interventions to support the
roll-out of malaria RDTs with updated clinical guidelines. The
effectiveness and cost-effectiveness of the interventions are
being evaluated in cluster-randomized trials at selected sites in
Cameroon and Nigeria (Wiseman et al. 2012a,b).
Methods
Study setting
The study was conducted at public and mission health facilities,
pharmacies and drug stores (henceforth referred to collectively
as outlets) in urban and rural areas of Cameroon and Nigeria,
where cluster-randomized trials would be conducted to evaluate
interventions to support the introduction of malaria RDTs
(Wiseman et al. 2012a,b). In Cameroon, the two sites were
Yaounde´ in the Centre region, which is urban and predomin-
antly French speaking, and Bamenda and seven rural districts
in the northwest region where English and pidgin-English are
widely spoken. In Nigeria, both sites were in Enugu State and
included urban communities in Enugu, and rural communities
in Udi.
Malaria is endemic in all four sites and occurs throughout the
year. At the time the study was conducted, the national malaria
treatment guidelines in both countries advised that malaria
should be suspected in all patients presenting with a fever or
history of fever, patients should be tested prior to treatment
where malaria testing was available, but in the absence of a
confirmed diagnosis presumptive treatment for uncomplicated
malaria was recommended (Ministry of Health of the Federal
Republic of Nigeria 2005; Ministry of Public Health of the
Republic of Cameroon 2008). ACT was the first-line treatment
for uncomplicated malaria (in all patients except pregnant
women), and was typically more expensive than other types of
antimalarial. In all outlets patients pay for the treatment they
receive, though there were exemptions for children under five
and pregnant women attending public facilities.
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In Cameroon and Nigeria, malaria is routinely treated using
antimalarials obtained at primary care facilities, outpatient
departments, pharmacies and drug stores. In the public and
mission facilities in Cameroon, malaria cases are treated by
doctors, nurses and pharmacists, and some facilities have a
laboratory technician able to conduct malaria microscopy
(Mangham et al. 2012). In Enugu State, malaria is often
treated in primary health centres and health posts that do not
offer malaria testing and are staffed by nurses, and health
extension workers (Mangham et al. 2011). Medicine retailers
were present in all study sites. In both countries, pharmacies
are legally required to have a trained pharmacist in order to sell
prescription-only and over-the-counter medicines, and they are
more prevalent in urban areas. Drug stores, also known as
patent medicine dealers, are formally recognized in the Nigerian
health system and staff are eligible to sell over-the-counter
medicines (including antimalarials) without any specific quali-
fications or training (Uzochukwu et al. 2009). In Cameroon,
drug stores operate under a business licence in the Anglophone
regions (which includes the northwest region) and are staffed
by providers with no or few health qualifications (Hughes et al.
2012).
Survey sampling and activities
Stratified cluster surveys were conducted with patients and
caregivers exiting health facilities, pharmacies and drug stores
and with providers working at these outlets between July and
December 2009. Sample size calculations were undertaken
separately for each country and sought to determine the
proportion of febrile patients seeking treatment that were
supplied an ACT, with a given level of precision (Mangham
et al. 2011, 2012). The sampling, conducted in March–May 2009,
was based on an enumeration of outlets that regularly dispense
antimalarials in the study sites. The enumeration was under-
taken for the study and involved fieldworkers locating all outlets
that were operating in each study site and recording the name,
type and global positioning system (GPS) co-ordinates of each.
In each country, two-stage sampling was used: first to randomly
select communities, having stratified by study site, and second to
select outlets that dispense antimalarials. In both countries, all
public primary care facilities were included and pharmacies and
drug stores were randomly selected with probability proportion-
ate to their number in the local community. In Cameroon, all
district hospitals and mission facilities in the selected commu-
nities were also included because they were also an important
source of treatment in Yaounde´ and Bamenda.
Questionnaires were developed and pre-tested at outlets that
were not included in the survey. The exit questionnaire
collected data about the patient, previous treatment seeking,
the consultation or interaction with the health care provider
and the treatment prescribed and received. Individuals were
eligible to complete the exit survey if they reported seeking
treatment for a fever, either for themselves or another (who
may or may not be present), the patient had no signs of severe
malaria, and they gave informed written consent. Providers
were surveyed to collect data on pre-service and in-service
training, their knowledge of the national treatment guidelines,
and their preference for treating patients with symptoms of
uncomplicated malaria. All providers that prescribed or
dispensed antimalarials, were available at the time of the
survey, and gave informed written consent were eligible to
participate. In addition, one provider at each outlet completed a
questionnaire which asked about the services and medicines
available and the procurement of antimalarials. All question-
naires were individually administered by trained fieldworkers
working under the supervision of site co-ordinators. Data were
double-entered and verified using Microsoft Access 2007
(Microsoft Inc., Redmond Washington) and data entry errors
were corrected to ensure consistency with the original form.
Data sources
Providers’ choice of antimalarial was investigated using patient
exit and provider survey data from Cameroon and Nigeria. Data
analysis was undertaken separately for each country. Exit
survey responses that fulfilled the following criteria were
included: (1) the patient or caregiver reported seeking treat-
ment for a fever; (2) the patient was not pregnant or under 6
months of age; (3) the patient or caregiver did not request a
specific medicine; (4) the patient had a presumptive or
confirmed malaria diagnosis (i.e. patients with a negative
malaria test result were excluded) and (5) an antimalarial was
prescribed or received (as shown in Figure 1).
Multilevel logistic regressions were used to investigate what
factors influenced providers’ choice of antimalarial. The de-
pendent variable was a binary outcome that indicates whether
or not the provider supplied an ACT (coded 1 if an ACT was
prescribed or received, and 0 otherwise). This variable was
derived from multiple questions about all medicines that were
prescribed or received whilst at the health facility, pharmacy or
drug store. Specifically, patients were asked if they had received
a prescription and if so, the fieldworker asked to see the
prescription so information could be recorded about the brand
and dose of medicines prescribed. Similarly, patients were
asked what medicines they had received whilst at the facility,
including any medicines consumed during the consultation.
Fieldworkers recorded the brand and dose of the medicines
received, where possible, by copying information about the
brand and dose of the medicines they were shown. Information
about the brand of medicines prescribed and received was used
to construct a variable indicating whether the patient had been
prescribed or received an antimalarial (yes/no) and whether the
antimalarial was an ACT (yes/no).
A theory-driven approach to model building was adopted.
Explanatory variables hypothesized to predict provider practice
included attributes of the provider, the patient, their inter-
action, and also the outlet in which the interaction took place
(Supplementary Appendix Table S1). The explanatory variables
were selected for inclusion in the econometric model with
reference to economic literature on agency theory, new insti-
tutional economics and behavioural economics (Arrow 1963;
Rabin 1998; Williamson 2000). To investigate the relationship
between providers’ knowledge and practice, the following
provider attributes were included: whether providers knew an
ACT was the recommended first-line treatment for uncompli-
cated malaria; their access to national malaria treatment
guidelines; whether they had attended in-service training on
malaria in the past 3 years; their highest level of pre-service
health training; whether they state ACT to be best treatment for
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uncomplicated malaria; and whether they report ACT is the
type of antimalarial their patients most often request. The last
two were included because there may be a difference between
providers’ knowledge of the malaria treatment guidelines, the
type of antimalarial they state they prefer, and the type of
antimalarial they perceive their patients prefer.
It was also assumed that providers may select treatment
based on the attributes of the patient or information obtained
during the interaction. The explanatory variables included the
following patient attributes: gender; age; household wealth
(relative to others who sought treatment); the education of the
patient or caregiver; whether treatment was sought within 2
days of the onset of fever; and whether previous treatment had
been sought for this illness episode, including whether an
antimalarial had been taken. In addition, relevant aspects of
the provider–patient interaction were: whether the patient was
examined; had a presumptive or confirmed malaria diagnosis;
and whether the provider was told that the patient had
diarrhoea or had been vomiting (as these symptoms may
affect the suitability of different medicines).
Attributes of the outlet may also have some bearing on the
treatment supplied, as contextual factors may constrain the
providers’ choice of treatment. Outlet attributes included in the
model were: outlet type; availability of ACT; whether antimal-
arials were received from a drug company representative
(whose promotional activities may be a source of information
or influence); and whether the outlet was in an urban or rural
community.
Relational databases
To investigate the relationship between providers’ knowledge
and practice, it was necessary to prepare a database that linked
patient exit responses (1) to information about the outlet and
(2) to the individual provider that was responsible for selecting
treatment. The outlet at which the exit survey was conducted
was known for all patients. Patients and caregivers were asked
to describe all the providers that were involved in supplying
care, and fieldworkers recorded the unique code that identified
each provider. When care was supplied by a single provider
Figure 1 Flow chart of patients and caregivers that sought for febrile illness at public and mission facilities, pharmacies and drug stores in
Cameroon and Nigeria.
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then it was straightforward to link the patient and provider
data if the provider had completed the survey. When care was
supplied by two or more providers and the cadre of all providers
was known, then it was assumed the more senior provider
decided which treatment to supply. For example, if care was
supplied by a registered nurse and a pharmacy attendant,
we assume the pharmacy attendant dispensed the type
of antimalarial prescribed by the registered nurse. In the
remaining cases, it was not possible to identify the individual
provider, and therefore data on provider attributes were
missing.
Econometric analysis
The econometric analysis involved multiple imputation and
multilevel logistic regression (van Buuren 2010; Carpenter and
Kenward 2013). There were almost complete data on patient,
and outlet attributes, though up to 26% of cases were missing
provider attributes due to challenges linking the databases
(Supplementary Appendix Table S1). The missing data were
binary or categorical responses and were non-monotone. The
proportion of missing provider data was disproportionately
greater at public and mission facilities in Cameroon, where ACT
was available, and at outlets located in urban communities.
Thus, the missing data were presumed to be conditional on
attributes of the outlet, which is known as ‘missing at random’
(MAR) in the statistical literature (Sterne et al. 2009).
Given the scale of missing data and suggested missingness
mechanism, multiple imputation using chained equations was
appropriate since analysis using only complete cases may be
biased (White and Carlin 2010). Multiple imputation is a
statistical technique for dealing with data ‘missing at random’
and is recommended when more than 10% of observations
would be excluded in a complete-case analysis (Burton and
Altman 2004). Multiple imputation allows for uncertainty
about the missing data by generating multiple copies of
datasets in which missing values are replaced by imputed
values, and then uses standard statistical methods to estimate
the model of interest using the imputed datasets (Sterne et al.
2009). Multiple imputation methods should respect the data
structure; ignoring the data hierarchy can lead to bias because
the variance of the imputation distribution would be under-
estimated (Goldstein et al. 2009). REALCOM-IMPUTE is stat-
istical software that enables multiple imputation for a two-level
model and fits the specified imputation model using Markov
Chain Monte Carlo methods (Carpenter et al. 2011).
The linked patient–provider data have a hierarchical structure,
as patients may be clustered by provider and by outlet. For
computational reasons it was not possible to take into account
all possible levels, and a two-level model was specified with
patients and provider attributes at level 1, and outlet attributes
at level 2. Outlet was defined as the level 2 identifier to reflect
the sampling strategy, the amount of clustering expected at this
level, and because it was known for every observation (while it
was not always possible to identify which provider supplied
treatment).
For a two-level logistic regression, the dependent variable !ij
is defined as the probability that the antimalarial supplied is an
ACT for patient i from outlet j, and [!ij=ð1 !ijÞ] is the
log odds that the antimalarial supplied is an ACT.
The econometric model for the providers’ choice of antimalarial
was specified as:
logitð!ijÞ ¼ þ Vij þ Pij þ Fj þ "ij þ uj "ij  Nð0; 2Þ
uj  Nð0; 2Þ
where  was the intercept; Vij were attributes of the provider
supplying an antimalarial to patient i at outlet j; Pij were
attributes of patient i receiving an antimalarial at outlet j; Fj
were attributes of outlet j; , l and  were the parameters
associated with the explanatory variables; "ij and uj were the
residuals at levels 1 and 2, respectively, and capture unobserved
variation, measurement and specification errors. The statistical
significance was measured using the Wald test, and P values
are reported along with 95% confidence intervals.
Multicollinearity amongst the explanatory variables was as-
sessed in the complete cases using the variance inflation factor.
We used the Ramsey RESET test to check for misspecification
of the regression model (Rice 2000). This is a general test for
problems associated with functional form and can identify
errors associated with omitted variable bias, measurement error
and simultaneity bias if they lead to nonlinearity in the
relationship between the dependent and explanatory variables
(Jones 2007). The models were also estimated without the
explanatory variable for providers’ stated preference to inves-
tigate simultaneity bias that would arise if providers’ preference
over alternative antimalarials was determined at the same time
they acquired knowledge of the recommended treatment. The
proportion of the total variance that was attributable to the
outlet level of the model was estimated using the variance
partition coefficient (VPC) (Hox 2010). The VPC is similar to
the intracluster correlation, though used when the dependent
variable is discrete, and calculated as:
VPC ¼ 2=ð2 þ 3:29Þ
where 2 is the variance at level 2 and the variance at level 1 is
the variance of the standard logistic distribution (2/3¼ 3.29).
Larger values of the VPC (0<VPC<1) indicate that the level
has greater potential to influence the value of the dependent
variable (Hox 2010).
Two-level logistic regressions were estimated using adaptive
quadrature to approximate the marginal likelihood by numer-
ical integration in Stata 12.1 (StataCorp 2009). The model was
initially estimated with data from each country using listwise
deletion, and therefore used only those cases that were
complete and have no missing data (also known as complete
cases). The model was subsequently estimated using data from
50 imputations generated by two-level multiple imputation
using chained equations completed using Stata 12.1 and
REALCOM-IMPUTE with a burn-in of 2000 and 500 further
updates between each imputation (White et al. 2011). To avoid
bias the imputation model used all variables that were included
the analysis model (White et al. 2011).
Results
Description of the sample
The linked patient–provider database contained data on 2451
cases of febrile illness that sought treatment at public and
mission health facilities and medicine retailers, with 871 cases
PROVIDERS’ PRACTICE AND MALARIA GUIDELINES 1133
from Cameroon and 1634 from Nigeria (Figure 1). Almost all
outlets and individuals approached were willing to participate
in the study: in Cameroon 11 outlets (5%), 10 providers (2%)
and 31 (3%) patients refused, while in Nigeria all outlets and
providers gave consent but 31 patients (2%) refused (Mangham
et al. 2011, 2012). The provider was presumed to be responsible
for diagnosis and treatment when the patient or caregiver
reported that they did not ask for a specific medicine. There
were 516 patients in Cameroon and 942 patients in Nigeria
eligible for malaria treatment, based on either a symptomatic or
confirmed diagnosis (having excluded cases which requested a
specific medicine and 45 patients from Cameroon that tested
negative for malaria). Of the eligible patients, 405 (79%)
patients in Cameroon and 641 (68%) patients in Nigeria were
supplied an antimalarial. In Cameroon, providers often chose to
supply ACT, (74% of antimalarials supplied), though quinine
either as a tablet or injection was also common (21%)
(Table 1). However, in Nigeria providers regularly supplied
sulphadoxine–pyrimethamine (40%) as well as ACT (37%), and
other alternatives included artesunate monotherapy (11%) and
chloroquine (10%).
Linking patients to the provider that supplied
treatment
Across the two countries 1046 patients were supplied an
antimalarial (Figure 2). Almost all patients and caregivers
were able to describe the providers they interacted with whilst
at the public or mission health facility, pharmacy or drug store
(396/405 in Cameroon and 634/641 in Nigeria). In Nigeria most
cases (527/641) involved interactions with a single provider,
while in Cameroon the majority of cases (291/405) involved
interaction with two or more providers. It was possible to link
the patient to details about the provider in 75% of cases (304/
405) in Cameroon and 80% of cases (512/641) in Nigeria
(Figure 2). In the remaining cases, the provider’s details were
unknown because the respondent was unable to recall one or
more of the providers who supplied care (9 in Cameroon and 7
in Nigeria); care was supplied by one or more providers who
did not complete the survey (74 in Cameroon and 102 in
Nigeria); or patients received care from multiple providers of
the same cadre (18 in Cameroon and 20 in Nigeria).
Provider, outlet and patient attributes
The febrile patients were linked to 119 providers working at 105
outlets in Cameroon and 107 providers working at 93 outlets in
Nigeria (Table 2). Approximately two-thirds of these providers
accurately reported ACT was the first-line treatment for
uncomplicated malaria, with better knowledge of the recom-
mended treatment reported among providers working at public
facilities. In Cameroon, 90% of providers at public facilities
knew ACT was recommended compared to 65% at mission
facilities, 50% at pharmacies and 45% at drug stores; while in
Nigeria, 79% of providers at public facilities, 73% at pharmacies
and 36% at drug stores accurately reported ACT was the
recommended first-line treatment. Providers’ access to malaria
treatment guidelines and training also differed by country and
type of outlet, with providers at public and mission health
facilities more likely to report having access to the national
malaria treatment guidelines than those working at pharmacies
and drug stores. Providers’ responses to survey questions on
which type of antimalarial their patients usually ask for and
which antimalarial is best for uncomplicated malaria also
varied by setting. It was also interesting to note there were 20
providers in Cameroon and 21 providers in Nigeria who knew
ACT was recommended but did not state it was their preferred
treatment for uncomplicated malaria. Almost all pharmacies
were located in urban communities. The majority of outlets had
ACT available at the time of the survey, though there was
considerable variation by type of outlet, ranging from 57% of
the drug stores surveyed in Cameroon to 100% of the
pharmacies surveyed in Nigeria.
The characteristics of febrile patients who relied on the
provider to select treatment and were supplied an antimalarial
are shown in Table 3. The proportions by gender and age group
were similar across the different types of outlet in Cameroon,
though in Nigeria proportionately more children under five
were treated at public facilities than at pharmacies and drug
stores. In both countries, there was some variation in the
education level of the person seeking treatment and household
wealth, with individuals at pharmacies having higher levels of
education and from wealthier quintiles. There were also notable
differences in the patient–provider interaction, as patients at
public and mission health facilities were more frequently
examined. Presumptive diagnosis of malaria was the norm in
all outlets, though 23% of patients at public and mission
Table 1 Providers’ choice of antimalarial, by country and type of outlet
Type of antimalarial Cameroon (N¼ 405) Nigeria (N¼ 641)
Public Mission Pharmacy Drug store Public Pharmacy Drug store
N % N % N % N % N % N % N %
N¼ 202 N¼ 80 N¼ 52 N¼ 71 N¼ 123 N¼ 323 N¼ 318
Artemisinin combination therapy (ACT) 164 81.2 52 65.0 51 98.1 32 45.1 158 48.9 24 40.0 53 20.5
Amodiaquine – – – – – – 5 7.0 4 1.2 1 1.7 1 0.4
Artesunate monotherapy 3 1.5 2 2.5 – – – – 30 9.3 10 16.7 29 11.2
Chloroquine – – – – – – 1 1.4 16 5.0 – – 51 19.8
Halofantrine – – – – – – – – 3 1.2 1 1.7 1 0.4
Quinine 35 17.3 22 27.5 – – 28 39.4 1 0.3 1 1.7 – –
Sulphadoxine–pyrimethamine (SP) – – 4 5.0 1 1.9 5 7.0 111 34.4 23 38.3 123 47.7
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facilities in Cameroon had their malaria diagnosis confirmed by
microscopy.
Factors influencing the providers’ decision to supply
ACT
The relationship between providers’ knowledge of the malaria
treatment guidelines and their decision to supply ACT was
examined in Cameroon and in Nigeria using univariable and
multivariable models (Tables 4 and 5). Analysis was conducted
using complete cases and once missing data had been imputed.
The specification of the multivariable models was assessed: the
results for Ramsey RESET tests were not significant and there
was no evidence of multicollinearity. The variable for providers’
stated preference was included in the final model since there
was no evidence of simultaneity bias. Also likelihood ratio tests
indicated model fit was significantly better when providers’
stated preference was included. Multivariable models without
the variable for providers’ stated preference are available
(Supplementary Tables Appendices S2 and S3).
There was no evidence of a relationship between providers’
knowledge and practice in the univariable analysis in either
Cameroon or Nigeria. However, the multivariable models
identified several attributes of providers, patients and outlets
that were significant predictors of providers supplying an ACT (at
the 10% level of significance). Providers in both countries were
more than twice as likely to supply ACT if they reported ACT was
the best type of antimalarial for uncomplicated malaria (Odds
ratio (OR)¼ 2.80, 95% confidence interval (CI)¼ 1.14–6.89,
P¼ 0.025 in Cameroon and OR¼ 2.54, 95% CI¼ 1.02–6.32,
Figure 2 Flow chart showing how patients were linked to providers.
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P¼ 0.044 in Nigeria). In Nigeria, this was the only provider
attribute that had a significant effect. In Cameroon, however,
there was also evidence that providers were more likely to select
ACT if they had reported it was the type of antimalarial that their
patients most often request (OR¼ 2.36, 95% CI¼ 0.92–6.06,
P¼ 0.075). In addition, once missing data had been imputed
the results suggest that pre-service training may have some
bearing on their choice (P¼ 0.092), and knowledge of the malaria
treatment guidelines may adversely affect their decision to supply
an ACT (OR¼ 0.39, 95% CI¼ 0.14–1.08, P¼ 0.070).
Providers’ choice of antimalarial was related to several patient
attributes, though there were notable differences between the
two countries. In Cameroon, providers were less likely to supply
an ACT if the patient had previously taken an antimalarial
(OR¼ 0.22, 95% CI¼ 0.17–0.64, P¼ 0.005) or had their diagno-
sis confirmed using microscopy (OR¼ 0.031, 95% CI¼ 0.13–
0.74, P¼ 0.008). Also, once missing data had been imputed
there was also some evidence that those from wealthier
quintiles were more likely to receive an ACT (P¼ 0.048). In
Nigeria, there was strong evidence that providers were more
likely to supply ACT to patients under 5 years of age (OR¼ 2.67,
95% CI¼ 1.54–4.63, P 0.001) and to male patients (OR¼ 1.85,
95% CI¼ 1.19–2.89, P¼ 0.007), though wealth was not signifi-
cant. The results also indicate that providers in Nigeria were
more likely to supply ACT when told the patient had diarrhoea or
had been vomiting (OR¼ 2.36, 95% CI¼ 1.38–4.04, P¼ 0.002),
though less likely to supply an ACT if it was the first time
treatment was sought for the illness episode (OR¼ 0.49, 95%
CI¼ 0.26–0.90, P¼ 0.023). As in Cameroon, patients with a
confirmed malaria diagnosis were less likely to receive an ACT
(OR¼ 0.23, 95% CI¼ 0.05–1.04, P¼ 0.057); however, it is im-
portant to recognize that only 2% of all patients in Nigeria had
their diagnosis confirmed by a malaria test.
In both countries, providers’ decision to supply an ACT was
correlated with attributes of the outlet. In Cameroon, patients
were more likely to receive an ACT if treatment was sought at a
pharmacy or public facility (P<0.001), while in Nigeria
providers were three times more likely to supply ACT if it
was in stock (OR¼ 3.25, 95% CI¼ 1.30–8.14, P¼ 0.012). Finally,
having controlled for a wide range of provider, outlet and
patient attributes, the VPC indicates that a substantial propor-
tion of the remaining heterogeneity can be attributed to
unobserved outlet-level factors.
Discussion
The analysis focused on the relationship between providers’
knowledge and practice, and was motivated by a need to design
Table 2 Provider and outlet attributes, by country and type of outlet
Attributes Cameroon (N¼ 405) Nigeria (N¼ 641)
Public Mission Pharmacy Drug store Public Pharmacy Drug store
N % N % N % N % N % N % N %
Provider N¼ 48 N¼ 20 N¼ 22 N¼ 29 N¼ 38 N¼ 22 N¼ 47
Knew ACT was first-line antimalariala 43 89.6 13 65.0 11 50.0 13 44.8 30 78.9 16 72.7 17 36.2
Reports has access to malaria guidelinesa 35 72.9 12 60.0 2 9.1 1 3.4 12 31.6 1 4.5 1 2.1
Has attended malaria traininga 23 47.9 5 25.0 6 27.3 1 3.4 12 31.6 4 18.2 14 29.8
Pre-service trainingb
Doctor 10 20.8 6 30.0 – – – – 6 15.8 – – – –
Nurse or midwife 25 52.1 5 25.0 3 13.6 3 10.3 5 13.2 2 9.1 – –
Pharmacist 1 2.1 0 0.0 10 45.5 2 6.9 – – 3 13.6 – –
Nurse assistant 7 14.6 6 30.0 2 9.1 15 51.7 – – – – –
CHO or CHEW – – – – 26 68.4 2 9.1 3 6.4
None (attendant or drug seller) 5 10.4 3 15.0 7 31.8 9 31.0 1 2.6 15 68.2 44 93.6
Reported patients usually ask for ACTa 22 45.8 8 40.0 18 81.8 9 31.0 11 28.9 12 54.5 8 17.0
Stated ACT was best antimalarial for
uncomplicated malariaa
38 79.2 9 45.0 15 68.2 23 79.3 22 57.9 19 86.4 24 51.1
Knew ACT was the first-line antimalarial but
did not state it was the best antimalarial
9 18.8 6 30.0 4 18.2 1 3.4 11 28.9 3 13.6 7 14.9
Outlet N¼ 35 N¼ 15 N¼ 25 N¼ 30 N¼ 20 N¼ 21 N¼ 52
Outlet had ACT in stock 28 80.0 13 86.7 23 92.0 17 56.7 14 70.0 21 100.0 38 73.1
Outlet receives antimalarials from drug company
representativea
– – 1 4.0 2 6.7 – 12 57.1 9 17.3
Urban/rural community
Urban 13 37.1 9 60.0 24 96.0 17 56.7 12 60.0 20 95.2 31 59.6
Rural 22 62.9 6 40.0 1 4.0 13 43.3 8 40.0 1 4.8 21 40.4
aSome observations were missing (see Table 1).
bCategories differ by country. In Cameroon: Doctor; Nurse or Midwife; Pharmacist; Nurse Assistant; None (includes attendants). In Nigeria: Doctor; Nurse or
Midwife; Pharmacist; Community Health Officer (CHO) or Community Health Extension Worker (CHEW); None (includes patent medicine dealers).
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interventions to support the introduction of malaria RDTs in
Cameroon and Nigeria. There was no evidence from either
country that a provider’s decision to supply ACT was
determined by their knowledge of the national malaria treat-
ment guidelines. There was, however, significant evidence from
both countries that providers were more likely to supply ACT if
they reported it was the best treatment for uncomplicated
malaria (Cameroon OR¼ 2.80, 95% CI¼ 1.14–6.89, P¼ 0.025;
Nigeria OR¼ 2.54 95% CI¼ 1.02–6.32, P¼ 0.044). This positive
association between providers’ stated and revealed preferences
highlights the importance of designing interventions that strive
to change what providers think and believe to be appropriate,
not only enhance what they know.
The results also showed that having access to a copy of the
clinical guidelines and access to malaria training was not
sufficient to ensure appropriate treatment. This also demon-
strates that conventional methods to disseminate clinical
guidelines are likely to have a limited effect on providers’
practice in the study sites. Evidence from similar studies at
public and mission facilities elsewhere in Africa have mixed
results: prescribing practices were predicted by the providers’
access to in-service training, guidelines or wall charts in Benin
and Kenya (Rowe et al. 2003; Zurovac et al. 2004, 2008a),
though not in Central African Republic, Malawi, Uganda and
Zambia, (Rowe et al. 2000, 2003; Zurovac et al. 2005, 2008b;
Osterholt et al. 2006.).
There was evidence from both countries that providers’ choice
of treatment can depend on their patients, though which
factors were statistically significant differed by setting.
It was interesting to find providers in Cameroon who reported
their patients prefer ACT were more likely to supply it.
There was also evidence to suggest the relative wealth of the
patient may be a predictor of receiving an ACT. These findings
were consistent with views expressed during focus group
discussions, in which providers from public and mission
facilities in the Cameroon study sites explained how their
practice would depend on what they perceive their patients
want from the consultation and can afford (Chandler et al.
2012).
Patient attributes were also relevant in Nigeria, where
providers’ decision to supply ACT was significantly associated
with the patient’s age and gender. Age was also found to be a
significant predictor in other studies, with providers more likely
to supply ACT to children than adults (Zurovac et al. 2008a,b).
In-depth interviews conducted at public health centres in
Kenya described how providers who were concerned about
stock-outs would reserve ACT for young children and patients
with more severe symptoms (Wasunna et al. 2008). In contrast
Table 3 Patient Attributes by country and type of outlet
Patient attributes Cameroon (N¼ 405) Nigeria (N¼ 641)
Public Mission Pharmacy Drug store Public Pharmacy Drug store
N N N N N N N
N¼ 202 N¼ 80 N¼ 52 N¼ 71 N¼ 323 N¼ 60 N¼ 258
Patient’s gendera
Male 100 49.5 33 41.3 27 51.9 32 45.1 141 43.7 32 53.3 129 50.0
Female 100 49.5 45 56.3 25 48.1 38 53.5 179 55.4 27 45.0 126 48.8
Patient’s age groupa
Under 5 years 61 30.2 19 23.8 15 28.8 16 22.5 122 37.8 7 11.7 32 12.4
5 years and over 136 67.3 61 76.3 37 71.2 55 77.5 199 61.6 53 88.3 223 86.4
Education of person who sought treatmenta
Tertiary 15 7.4 14 17.5 18 34.6 8 11.3 67 20.7 28 46.7 54 20.9
Secondary 86 42.6 29 36.3 22 42.3 29 40.8 150 46.4 26 43.3 119 46.1
None or primary 98 48.5 37 46.3 11 21.2 33 46.5 93 28.8 5 8.3 80 31.0
Patients’ wealth quintile (relative to other patients)
Least poor 21 10.4 9 11.3 19 36.5 5 7.0 46 14.2 19 31.7 25 9.7
Fourth 24 11.9 21 26.3 12 23.1 9 12.7 48 14.9 18 30.0 50 19.4
Third 40 19.8 18 22.5 11 21.2 13 18.3 72 22.3 9 15.0 55 21.3
Second 44 21.8 13 16.3 7 13.5 26 36.6 82 25.4 11 18.3 56 21.7
Poorest 73 36.1 19 23.8 3 5.8 18 25.4 75 23.2 3 5.0 72 27.9
Treatment was sought within 2 days 69 34.2 24 30.0 32 61.5 36 50.7 131 40.6 40 66.7 164 63.6
First time treatment was sought 125 61.9 39 48.8 39 75.0 57 80.3 220 68.1 48 80.0 194 75.2
Patient had previously taken an antimalarial 19 9.4 20 25.0 6 11.5 4 5.6 34 10.5 4 6.7 14 5.4
Provider was told patient had diarrhoea or been vomiting 27 13.4 14 17.5 4 7.7 3 4.2 70 21.7 13 21.7 41 15.9
Patient was examined by provider 175 86.6 73 91.3 14 26.9 21 29.6 228 70.6 7 11.7 39 15.1
Patient reported malaria was confirmed 47 23.3 18 22.5 2 3.8 – – 16 5.0 – – – –
aSome observations were missing (see Table 1).
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Table 4 Factors associated with providers’ decision to supply ACT in Cameroon
Complete cases Multiple imputation
Number of patients 304 281 405 405
Number of outlets 91 84 105 105
Fixed effects OR (95% CI) P value OR
(95% CI)
P value OR
(95% CI)
P value OR (95% CI) P value
Level 1: Patient–provider interaction
Provider knew ACT is first-line antimalarial for
uncomplicated malaria
0.84
(0.33–2.13)
0.709 0.39
(0.11–1.35)
0.138 0.61
(0.28–1.33)
0.216 0.39 (0.14–1.08) 0.070
Provider had access to malaria guidelines 0.59 (0.20–1.80) 0.354 1.00 (0.37–2.70) 0.992
Provider had attended malaria training
in past 3 years
1.31 (0.46–3.74) 0.608 1.73 (0.63–4.76) 0.289
Provider’s pre-service
Doctor 0.91 (0.17–5.02) 0.458 2.78 (0.53–14.46) 0.092
Nurse/midwife 0.41 (0.10–1.72) 1.06 (0.26–4.36)
Pharmacist 0.53 (0.03–9.36) 0.21 (0.03–1.65)
Nurse assistant 1.32 (0.33–5.28) 2.90 (0.70–11.98)
None (attendant/drug seller) 1.0 1.0
Provider stated patients usually ask for ACT 2.60 (0.92–7.31) 0.070 2.36 (0.92–6.06) 0.075
Provider stated ACT was best antimalarial
for uncomplicated malaria
3.55 (1.28–9.88) 0.015 2.80 (1.14–6.89) 0.025
Patient was male 1.00 (0.47–2.12) 0.996 1.06 (0.56–1.99) 0.856
Patient was under 5 years of age 1.87 (0.72–4.77) 0.191 1.45 (0.67–3.13) 0.345
Education of person seeking treatment
Tertiary 0.42 (0.10–1.87) 0.490 0.67 (0.21–2.19) 0.733
Secondary 0.68 (0.27–1.70) 0.77 (0.36–1.65)
None or primary 1.0 1.0
Patient’s wealth quintile
Least Poor 3.63 (0.68–19.51) 0.279 2.62 (0.64–10.71) 0.048
Fourth 6.31 (1.23–32.20) 6.46 (1.73–24.13)
Third 1.77 (0.53–5.86) 1.63 (0.58–4.60)
Second 1.68 (0.63–4.50) 1.10 (0.45–2.69)
Poorest 1.0 1.0
Treatment was sought within 2 days 1.22 (0.53–2.82) 0.635 1.02 (0.51–2.05) 0.956
First time treatment was sought 0.24 (0.07–0.79) 0.019 0.41 (0.17–1.02) 0.056
Patient had previously taken an antimalarial 0.08 (0.02–0.39) 0.002 0.22 (0.07–0.64) 0.005
Provider was told patient has diarrhoea or
been vomiting
1.07 (0.33–3.47) 0.908 0.77 (0.28–2.08) 0.603
Patient was examined by provider 0.90 (0.33–2.45) 0.839 1.08 (0.43–2.72) 0.872
Patient had a confirmed malaria diagnosis 0.33 (0.12–0.91) 0.032 0.31 (0.13–0.74) 0.008
Level 2: Outlet
Type of outlet
Public 22.46 (3.86–130.69) 0.002 7.38 (1.53–35.57) <0.001
Mission 7.69 (1.16–50.80) 2.23 (0.45–11.08)
Pharmacy 72.63 (3.84–1372.3) 203.38 (13.10–3156.3)
Drug store 1.0 1.0
Outlet had ACT in stock 1.85 (0.67–5.13) 0.238 2.15 (0.74–6.26) 0.160
Outlet usually receives antimalarial from
drug company representative
1.75 (0.15–19.81) 0.650 1.43 (0.10–20.52) 0.791
Outlet was in an urban community 0.69 (0.25–1.88) 0.470 0.70 (0.26–1.87) 0.481
Constant 4.16
(1.76–9.87)
0.001 0.73 (0.10–5.18) 0.753 5.47
(2.63–11.37)
<0.001 0.38 (0.06–2.32) 0.296
Random effects
Residual SD 1.42
(0.91–2.21)
0.77 (0.23–2.58) 1.37
(0.92–2.04)
1.12 (0.67–1.86)
VPC 0.38 0.15 0.36 0.28
SD, Standard Deviation.
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to similar studies, gender was shown to be an important
predictor of the treatment supplied and further research on this
would be valuable. Although we cannot comment on the
relative severity of febrile illness among the patients in our
sample, it was intriguing to find providers were less likely to
supply ACT to patients seeking treatment for the first time or
with a confirmed diagnosis. Given the small number of patients
that reported having a positive malaria test, we are cautious
Table 5 Factors associated with providers’ decision to supply ACT in Nigeria
Complete cases Multiple imputation
Number of patients 473 423 641 641
Number of outlets 73 71 93 93
Fixed effects OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Level 1: patient–provider interaction
Provider knew ACT is first-line antimalarial
for uncomplicated malaria
1.66 (0.70–3.90) 0.247 1.08 (0.44–2.66) 0.869 1.69 (0.76–3.75) 0.196 1.08 (0.50–2.33) 0.851
Provider had access to malaria guidelines 0.83 (0.25–2.76) 0.761 1.54 (0.57–4.18) 0.392
Provider had attended malaria training in
past 3 years
0.66 (0.29–1.49) 0.316 0.69 (0.33–1.46) 0.332
Provider’s pre-service training
Doctor or nurse/midwife or pharmacista 2.18 (0.39–12.22) 0.453 1.75 (0.41–7.48) 0.717
CHO or CHEW 2.66 (0.58–12.16) 1.62 (0.41–6.34)
None (attendant/drug seller) 1.0 1.0
Provider stated patients usually ask for ACT 1.41 (0.29–1.49) 0.458 1.38 (0.62–3.07) 0.429
Provider stated ACT was best antimalarial
for uncomplicated malaria
2.54 (0.92–7.00) 0.071 2.54 (1.02–6.32) 0.044
Patient was male 1.61 (0.92–2.82) 0.093 1.85 (1.19–2.89) 0.007
Patient was under 5 years of age 3.84 (1.91–7.73) <0.001 2.67 (1.54–4.63) <0.001
Education of person seeking treatment
Tertiary 0.91 (0.37–2.26) 0.903 1.37 (0.67–2.78) 0.643
Secondary 0.84 (0.39–1.80) 1.08 (0.60–1.96)
None or primary 1.0 1.0
Patient’s wealth quintile
Least Poor 1.35 (0.40–4.62) 0.951 1.39 (0.54–3.60) 0.962
Fourth 1.40 (0.43–4.58) 1.32 (0.54–3.25)
Third 1.57 (0.52–4.80) 1.30 (0.55–3.09)
Second 1.36 (0.64–3.45) 1.30 (0.62–2.73)
Poorest 1.0 1.0
Treatment was sought within 2 days 1.75 (0.91–3.39) 0.095 1.45 (0.87–2.40) 0.151
First time treatment was sought 0.56 (0.25–1.25) 0.155 0.49 (0.26–0.90) 0.023
Patient had previously taken an antimalarial 1.80 (0.59–5.51) 0.300 1.01 (0.43–2.41) 0.976
Provider was told patient has diarrhoea
or been vomiting
2.39 (1.18–4.82) 0.015 2.36 (1.38–4.04) 0.002
Patient was examined by provider 1.06 (0.49–2.27) 0.885 1.29 (0.71–2.35) 0.408
Patient had a confirmed malaria diagnosis 0.06 (0.00–0.79) 0.033 0.23 (0.05–1.04) 0.057
Level 2: outlet
Type of outlet
Public 2.83 (0.51–15.80) 0.380 2.22 (0.50–9.94) 0.558
Pharmacy 0.78 (0.13–4.51) 1.25 (0.36–4.33)
Drug store 1.0 1.0
Outlet had ACT in stock 3.24 (1.05–9.96) 0.040 3.25 (1.30–8.14) 0.012
Outlet usually receives antimalarial from
drug company representative
1.93 (0.44–8.55) 0.386 1.04 (0.34–3.14) 0.947
Outlet was in an urban community 1.70 (0.50–5.72) 0.393 1.49 (0.54–4.09) 0.442
Constant 0.21 (0.10–0.46) <0.001 0.01 (0.00–0.06) <0.001 0.23 (0.12–0.45) <0.001 0.02 (0.00–0.06) <0.001
Random effects
Residual SD 1.73 (1.23–2.42) 1.06 (0.65–1.73) 1.68 (1.25–2.25) 0.99 (0.66–1.48)
VPC 0.48 0.26 0.46 0.23
aCategories were grouped for the analysis since there were few observations in each category and all these grades have received formal pre-service training.
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about drawing conclusions on the choice of antimalarial
following a confirmed diagnosis, though note that the test-
positive patients not supplied ACT were treated with an
antimalarial recommended for severe malaria, and these cases
were clustered in 14 public and mission facilities in Cameroon
and 3 public facilities in Nigeria. We were also unable to
investigate whether timing or length of the consultation were
important, which were significant predictors some studies
(Rowe et al. 2003; Zurovac et al. 2004, 2005; Osterholt et al.
2006).
Contextual factors were also associated with providers’
practice, and as there were substantial differences between
the two countries, the findings highlight the importance
of understanding the local context when designing public
health interventions. It was not surprising that providers
were more likely to supply ACT if it was in stock, though
having ACT available was not a prerequisite and providers could
prescribe ACT and advise it should be obtained elsewhere.
It should also be noted that the exit survey would not
have captured any cases where the provider recommended
ACT and the patient or caregiver opted for an alternative.
Furthermore, given the extent to which variation in providers’
practice was attributed to unobserved outlet-level factors,
it would be interesting to conduct further research to explore
how the institutional environment can influence providers’
practice.
Before concluding some limitations are acknowledged. While
several factors significantly predicted whether a provider
supplied an ACT, it is possible others were not identified
because the sample size was restricted to a subset of exit survey
respondents who did not request a specific medicine, had a
presumptive or confirmed malaria diagnosis, and were supplied
an antimalarial. Also, two assumptions were made to prepare
the data for analysis: the more senior cadre selected treatment
if patients were seen by more than one provider, and data were
MAR. The first assumption was based on the process of care
that we observed at many health outlets: junior staff record
signs and symptoms and direct patients to the relevant senior
health worker for a consultation, treatment is prescribed during
the consultation, and prescribed medicines are obtained from a
pharmacy attendant. At pharmacies and drug stores the process
is less structured, though where a pharmacist and a sales
attendant were involved we observed the pharmacist giving
advice and recommending medicines, while the attendant
administered the retail transaction. The second assumption
that data were MAR was critical to the multiple imputation.
The observed pattern of missingness was consistent with our
expectation that provider attributes were more likely to be
missing at larger outlets and in urban communities. We
acknowledge, however, that it is not possible to determine
whether data were MAR, as defined in the statistical literature
(White et al. 2011). Similarly, since the missing data can never
be known, we cannot ascertain whether differences between
the complete case and multiple imputation results, such as
those observed in Cameroon for the effect of pre-service
training and knowledge, arise because the complete cases are
biased, because multiple imputation depends on the MAR
assumption, or because of the specification of the imputation
model (White et al. 2011).
Conclusions
As governments prepare to introduce malaria RDTs in public
and private sectors, clinical guidelines will be updated to
include guidance on the new type of diagnostic test and
dissemination strategies will be developed. The introduction of
RDTs, with revised guidelines, presents an opportunity to
improve providers’ practice, not only by increasing the propor-
tion of patients that are tested prior to treatment, but also the
proportion of patients that receive the recommended treatment.
The results of this investigation suggest that conventional
public health interventions that ensure providers have access to
the guidelines, and know the treatment algorithm will not be
enough to change providers’ practice. The findings highlight
that public health interventions to improve the treatment of
uncomplicated malaria should strive to change what providers
prefer, rather than focus on what they know. In developing
interventions, the differences between the two countries high-
light the need to understand the local context, as providers’
treatment decisions may depend on what they perceive their
patients prefer or can afford as well as information about
their symptoms or previous treatment seeking. In addition,
the findings suggest it will be important to emphasize that
the treatment algorithm should not depend on patient attri-
butes, such as age or wealth, and that ACT is suitable
for patients with a confirmed malaria diagnosis, unless they
have symptoms of severe malaria or are pregnant. Finally,
it should be recognized that working environment can con-
strain providers’ practice, and providers can only adhere to
clinical guidelines if essential medicines and supplies are
available.
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